Compare ELTX & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | DSP |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.4M | 213.3M |
| IPO Year | 2014 | 2021 |
| Metric | ELTX | DSP |
|---|---|---|
| Price | $14.77 | $11.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $18.00 | $17.81 |
| AVG Volume (30 Days) | 126.0K | ★ 256.8K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.29 | ★ 157.14 |
| EPS | N/A | ★ N/A |
| Revenue | $2,301,000.00 | ★ $344,201,000.00 |
| Revenue This Year | N/A | $20.27 |
| Revenue Next Year | N/A | $16.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.00 |
| 52 Week Low | $7.37 | $8.11 |
| 52 Week High | $16.00 | $15.18 |
| Indicator | ELTX | DSP |
|---|---|---|
| Relative Strength Index (RSI) | 67.60 | 46.68 |
| Support Level | $9.76 | $11.09 |
| Resistance Level | N/A | $12.61 |
| Average True Range (ATR) | 1.30 | 0.88 |
| MACD | 0.35 | -0.14 |
| Stochastic Oscillator | 79.67 | 16.74 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.